SIMCERE PHARMA (02096.HK): SIM0712 Cleared for Atopic Dermatitis Trial
NewTimeSpace News: On 16 November 2026, Simcere Pharmaceutical Group Limited (stock code: 02096) announced that SIM0712, an oral small molecule degrader targeting signal transducer and activator of transcription 6 (STAT6) independently developed by the Group, has received a Clinical Trial Approval from the National Medical Products Administration of China, with a clinical trial proposed for the treatment of atopic dermatitis.
SIM0712 was developed on the Group's Proteolysis Targeting Chimera (PROTAC) platform. By binding to the SH2 domain of STAT6, it induces degradation of the STAT6 protein, thereby blocking interleukin-4 (IL-4) and interleukin-13 (IL-13)-mediated signalling and suppressing type 2 inflammation. Preclinical studies showed that the molecule induced STAT6 degradation in human immune and stromal cells at picomolar concentrations, with no obvious degradation of the related STAT1 to STAT5 proteins or CRBN-related substrates.
According to the announcement, SIM0712 showed marked anti-inflammatory efficacy in mouse models of atopic dermatitis and asthma, and favourable pharmacokinetics in rats, dogs and cynomolgus monkeys. The Group sees broad potential across type 2 inflammatory diseases including atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic oesophagitis and chronic rhinosinusitis with nasal polyps, with a "one drug, multiple indications" profile. The Group focuses on neuroscience, oncology, autoimmune and anti-infective fields.
- SIMCERE PHARMA (02096.HK): Sublingual Stroke Drug Added to 2026 National Reimbursement List
- SIMCERE PHARMA (02096.HK): SIM0725 Cleared for Clinical Trial in Autoimmune Diseases
- SIMCERE PHARMA (02096.HK): SIM0709 trial cleared in Germany
- SIMCERE PHARMA (02096.HK): zemprocitinib RA NDA accepted by NMPA
- SIMCERE PHARMA (02096.HK): Zemprocitinib dermatology rights secured